Aktis Oncology Starts Phase 1b Trial for AKY-2519
Aktis Oncology initiated its third Phase 1b clinical trial of AKY-2519 to treat lung cancer, expanding its portfolio of targeted radiopharmaceuticals. The update reflects the company's ongoing progress in clinical development.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed